HCM - Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
- OrbiMed Asia V plans to raise $1.1 billion, OrbiMed Flagship IX seeks $1.9 billion and OrbiMed Royalty & Credit Opportunities $1.75 billion.
- Shanghai Jemincare Pharmaceuticals out-licensed global rights (ex-China) for a novel pain medication to Orion Corporation, a Finnish pharmaceutical company.
- Shanghai Newsoara Biopharma has been cleared to proceed with its China Phase III trial of LB1148, which is designed to accelerate the return of bowel function in adult patients following bowel/abdominal surgery.
For further details see:
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund